Vertex Mempersembahkan Data Jangka Panjang Positif Mengenai CASGEVY™ (exagamglogene autotemcel) di Pertemuan dan Pameran Tahunan American Society of Hematology (ASH) dan Memberikan Pembaruan Program
of CASGEVY in patients with TDT and SCD, respectively. The CLIMB-131 trial is also assessing the safety and efficacy of CASGEVY in patients with TDT. These trials have shown promising results in reducing or eliminating the need for transfusions in TDT patients and reducing vaso-occlusive crises in SCD patients. The safety profile of CASGEVY remains … Baca Selengkapnya